Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019041733) INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/041733 International Application No.: PCT/CN2018/073662
Publication Date: 07.03.2019 International Filing Date: 22.01.2018
IPC:
A61K 47/55 (2017.01) ,A61K 47/60 (2017.01) ,A61K 31/5377 (2006.01) ,A61K 31/4184 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/517 (2006.01) ,A61K 31/4745 (2006.01) ,A61K 31/454 (2006.01) ,A61K 31/337 (2006.01) ,A61P 35/00 (2006.01)
[IPC code unknown for A61K 47/55][IPC code unknown for A61K 47/60]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4738
ortho- or peri-condensed with heterocyclic ring systems
4745
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
337
having four-membered rings, e.g. taxol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
重庆阿普格雷生物科技有限公司 CHONGQING UPGRA BIOLOGICAL SCI. & TECH., LTD. [CN/CN]; 中国重庆市 渝北区双龙湖街道仙桃数据谷东路19号 19 E. Xiantao Bigdata Valley Rd., Shuanglong Lake St., Yubei District Chongqing 401120, CN
Inventors:
李高全 LI, Gaoquan; CN
汪斌 WANG, Bin; CN
李大军 LI, Dajun; CN
张倩 ZHANG, Qian; CN
黄蕾 HUANG, Lei; CN
陈毛芬 CHEN, Maofen; CN
吴晓丹 WU, Xiaodan; CN
彭良艳 PENG, Liangyan; CN
何婷婷 HE, Tingting; CN
张艳艳 ZHANG, Yanyan; CN
唐云 TANG, Yun; CN
刘欢 LIU, Huan; CN
税举媛 SHUI, Jvyuan; CN
张翠芳 ZHANG, Cuifang; CN
李建环 LI, Jianhuan; CN
Agent:
北京超凡志成知识产权代理事务所(普通合伙) CHOFN INTELLECTUAL PROPERTY; 中国北京市 海淀区北四环西路68号左岸工社1215-1218室 Room 1215-1218, Floor 12 Left Bank Community No.68 Beisihuanxilu, Haidian District Beijing 100080, CN
Priority Data:
201710761572530.08.2017CN
Title (EN) INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF
(FR) MÉDICAMENT INTERMÉDIAIRE AYANT UNE ACTIVITÉ ANTICANCÉREUSE SYNERGIQUE ET UN MÉDICAMENT ANTICANCÉREUX SYNERGIQUE COUPLÉ AU POLYÉTHYLÈNE GLYCOL, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION
(ZH) 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
Abstract:
(EN) Disclosed are an intermediate drug with a synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a preparation method therefor and the use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs can achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among drugs and pharmacokinetics when taking various anticancer drugs alone, facilitates overcoming the multidrug resistance of cancers, has a synergistic effect, and can be used for preparing anticancer drugs and for treating cancers.
(FR) L'invention concerne un médicament intermédiaire ayant une activité anticancéreuse synergique et un médicament anticancéreux synergique couplé au polyéthylène glycol, et leur procédé de préparation et leur utilisation. Le médicament intermédiaire a la formule structurale générale de (I), et le médicament anticancéreux synergique couplé au polyéthylène glycol a la formule structurale générale de (II). Les médicaments peuvent obtenir la médication combinée de divers médicaments anticancéreux et éviter la réaction toxique provoquée par l'interaction entre des médicaments et la pharmacocinétique lors de la prise de divers médicaments anticancéreux seuls, facilitent la surmonter de la résistance multiple aux médicaments des cancers, présentent un effet synergique, et peuvent être utilisés pour préparer des médicaments anticancéreux et pour traiter des cancers.
(ZH) 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物,其制备方法和应用。该中间体药物的结构通式为(I),聚乙二醇偶联协同抗癌药物的结构通式为(II),上述药物能够实现多种抗癌药物之间的联合用药,避免在单独服用多种抗癌药物时由于药物之间的相互影响以及药代动力学而导致的毒性反应,且有利于克服癌症的多药耐药性,具有协同增效的作用,可用于制备抗癌药物及用于治疗癌症。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)